The abstract is read at the publisher; the summary is JClub's.
Pegylated diacyllipid–conjugated TNF-α–neutralizing Ab and CTLA4 in collagen-induced arthritis substantially improve therapeutic efficacy, with two DP moieties outperforming single-DP conjugates.
- Why it matters: Antibody-based bDMARDs improve rheumatoid arthritis but often show limited efficacy, motivating delivery strategies that better reach inflamed joints and lymph nodes for stronger immunosuppression.
- What they did: The authors conjugated Ab-based bDMARDs with pegylated diacyllipid (DP) motifs to promote albumin hitchhiking after subcutaneous dosing, then tested targeting and efficacy in a collagen-induced arthritis model.
- The result: DP-modified bDMARDs enhanced and concurrently targeted inflamed joints and lymph nodes, improving efficacy for two representative drugs without detectable additional safety risks, and multivalent DP conjugation increased albumin engagement.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.